Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation

dc.contributor.authorBiayna, Josep
dc.contributor.authorMazuelas, Helena
dc.contributor.authorGel Moreno, Bernat
dc.contributor.authorTerribas, Ernest
dc.contributor.authorDumbovic, Gabrijela
dc.contributor.authorRosas, Inma
dc.contributor.authorFernández Rodríguez, Juana
dc.contributor.authorBlanco Guillermo, Ignacio
dc.contributor.authorCastellanos, Elisabeth
dc.contributor.authorCarrió, Meritxell
dc.contributor.authorLázaro García, Conxi
dc.contributor.authorSerra Arenas, Eduard,
dc.date.accessioned2021-04-23T09:25:11Z
dc.date.available2021-04-23T09:25:11Z
dc.date.issued2021-02-11
dc.date.updated2021-04-22T10:43:00Z
dc.description.abstractNeurofibromatosis Type 1 (NF1) is a genetic condition affecting approximately 1:3500 persons worldwide. The NF1 gene codes for neurofibromin protein, a GTPase activating protein (GAP) and a negative regulator of RAS. The NF1 gene undergoes alternative splicing of exon 23a (E23a) that codes for 21 amino acids placed at the center of the GAP related domain (GRD). E23a-containing type II neurofibromin exhibits a weaker Ras-GAP activity compared to E23a-less type I isoform. Exon E23a has been related with the cognitive impairment present in NF1 individuals. We designed antisense Phosphorodiamidate Morpholino Oligomers (PMOs) to modulate E23a alternative splicing at physiological conditions of gene expression and tested their impact during PC12 cell line neuronal differentiation. Results show that any dynamic modification of the natural ratio between type I and type II isoforms disturbed neuronal differentiation, altering the proper formation of neurites and deregulating both the MAPK/ERK and cAMP/PKA signaling pathways. Our results suggest an opposite regulation of these pathways by neurofibromin and the possible existence of a feedback loop sensing neurofibromin-related signaling. The present work illustrates the utility of PMOs to study alternative splicing that could be applied to other alternatively spliced genes in vitro and in vivo.
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid33574490
dc.identifier.urihttps://hdl.handle.net/2445/176673
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-021-83152-w
dc.relation.ispartofScientific Reports, 2021, vol. 11
dc.relation.urihttps://doi.org/10.1038/s41598-021-83152-w
dc.rightscc by (c) Biayna et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationNeurofibromatosi
dc.subject.classificationOligonucleòtids
dc.subject.otherNeurofibromatosis
dc.subject.otherOligonucleotides
dc.titleUsing antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s41598-021-83152-w.pdf
Mida:
10.36 MB
Format:
Adobe Portable Document Format